| David Andrew Mong, MD | |
|
13123 E 16th Ave, Department Of Radiology, Box 125, Aurora, CO 80045-7106 | |
| (720) 777-8574 | |
| Not Available |
| Full Name | David Andrew Mong |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 25 Years |
| Location | 13123 E 16th Ave, Aurora, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437100815 | NPI | - | NPPES |
| 1012981940001 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | MD424169 (Pennsylvania) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | DR.0045542 (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Children's Hospital Colorado | Aurora, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Physicians Incorporated | 3476465667 | 2657 |
News Archive
Oncolytics Biotech Inc. announced today that it has entered into an "at-the-market" (ATM) equity distribution agreement with Canaccord Genuity Inc. acting as sole agent.
Ligand Pharmaceuticals Incorporated announced that its partner Prism Pharmaceuticals has entered into a definitive agreement to be acquired by Baxter International Inc.. Prism Pharmaceuticals recently received FDA approval for Nexterone®, an antiarrhythmic agent which Ligand (through its CyDex Pharmaceuticals subsidiary) originally developed with its patented Captisol® formulation technology and licensed to Prism in 2006.
President Obama would love nothing more than Republicans' providing him a bully pulpit and big stick with which he can beat them daily through the 2014 midterm elections. That's what the Republicans would give Mr. Obama if they shut down the government by trying to defund Obamacare in the Continuing Resolution (CR) to fund the federal government after October 1. That's because the Continuing Resolution only affects discretionary spending. Virtually all of Obamacare costs are mandatory spending, unaffected by what's in the CR (Karl Rove, 7/26).
Men with benign prostatic hyperplasia (BPH), a condition in which the prostate is enlarged but not cancerous, have a new, breakthrough treatment option that is less invasive and has fewer complications than other minimally invasive treatments, such as transurethral resection of the prostate and surgical options, according to research presented at the Society of Interventional Radiology's Annual Scientific Meeting.
› Verified 3 days ago
| Entity Name | University Physicians Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962461889 PECOS PAC ID: 3476465667 Enrollment ID: O20031105000375 |
News Archive
Oncolytics Biotech Inc. announced today that it has entered into an "at-the-market" (ATM) equity distribution agreement with Canaccord Genuity Inc. acting as sole agent.
Ligand Pharmaceuticals Incorporated announced that its partner Prism Pharmaceuticals has entered into a definitive agreement to be acquired by Baxter International Inc.. Prism Pharmaceuticals recently received FDA approval for Nexterone®, an antiarrhythmic agent which Ligand (through its CyDex Pharmaceuticals subsidiary) originally developed with its patented Captisol® formulation technology and licensed to Prism in 2006.
President Obama would love nothing more than Republicans' providing him a bully pulpit and big stick with which he can beat them daily through the 2014 midterm elections. That's what the Republicans would give Mr. Obama if they shut down the government by trying to defund Obamacare in the Continuing Resolution (CR) to fund the federal government after October 1. That's because the Continuing Resolution only affects discretionary spending. Virtually all of Obamacare costs are mandatory spending, unaffected by what's in the CR (Karl Rove, 7/26).
Men with benign prostatic hyperplasia (BPH), a condition in which the prostate is enlarged but not cancerous, have a new, breakthrough treatment option that is less invasive and has fewer complications than other minimally invasive treatments, such as transurethral resection of the prostate and surgical options, according to research presented at the Society of Interventional Radiology's Annual Scientific Meeting.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David Andrew Mong, MD 13123 E 16th Ave, Department Of Radiology, Box 125, Aurora, CO 80045-7106 Ph: (720) 777-8574 | David Andrew Mong, MD 13123 E 16th Ave, Department Of Radiology, Box 125, Aurora, CO 80045-7106 Ph: (720) 777-8574 |
News Archive
Oncolytics Biotech Inc. announced today that it has entered into an "at-the-market" (ATM) equity distribution agreement with Canaccord Genuity Inc. acting as sole agent.
Ligand Pharmaceuticals Incorporated announced that its partner Prism Pharmaceuticals has entered into a definitive agreement to be acquired by Baxter International Inc.. Prism Pharmaceuticals recently received FDA approval for Nexterone®, an antiarrhythmic agent which Ligand (through its CyDex Pharmaceuticals subsidiary) originally developed with its patented Captisol® formulation technology and licensed to Prism in 2006.
President Obama would love nothing more than Republicans' providing him a bully pulpit and big stick with which he can beat them daily through the 2014 midterm elections. That's what the Republicans would give Mr. Obama if they shut down the government by trying to defund Obamacare in the Continuing Resolution (CR) to fund the federal government after October 1. That's because the Continuing Resolution only affects discretionary spending. Virtually all of Obamacare costs are mandatory spending, unaffected by what's in the CR (Karl Rove, 7/26).
Men with benign prostatic hyperplasia (BPH), a condition in which the prostate is enlarged but not cancerous, have a new, breakthrough treatment option that is less invasive and has fewer complications than other minimally invasive treatments, such as transurethral resection of the prostate and surgical options, according to research presented at the Society of Interventional Radiology's Annual Scientific Meeting.
› Verified 3 days ago
Dr. Tyler Robin, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1665 Aurora Ct, Suite 1032, Msf706, Aurora, CO 80045 Phone: 720-848-0100 | |
Dr. Ryan Michael Lanning, M.D., PHD. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1665 Aurora Ct, Suite 1032, Aurora, CO 80045 Phone: 720-848-0100 Fax: 720-848-0113 | |
Stephanie C Hsu, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 13123 E 16th Ave, Aurora, CO 80045 Phone: 720-777-1234 | |
Thomas Suby-long, MD Radiology Medicare: Medicare Enrolled Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Alan E Evans, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Ajay Agarwal, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Eugene E Bourne, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 6428 S Blackhawk Way, Aurora, CO 80016 Phone: 720-870-5109 |